Mendel Scott 4

4 · Akoya Biosciences, Inc. · Filed Jul 10, 2025

Form 4

Period: 2025-07-08

Director

Transactions

Other
Stock Option (right to buy)
2025-07-08−44,959→ 0 total
Exercise: $2.68Exp: 2034-10-02→ Common Stock (44,959 underlying)
Other
Common Stock
2025-07-08−28,500→ 0 total
Other
Stock Option (right to buy)
2025-07-08−30,549→ 0 total
Exercise: $11.24Exp: 2032-06-01→ Common Stock (30,549 underlying)
Other
Stock Option (right to buy)
2025-07-08−50,000→ 0 total
Exercise: $2.01Exp: 2034-06-04→ Common Stock (50,000 underlying)
Other
Stock Option (right to buy)
2025-07-08−35,562→ 0 total
Exercise: $19.94Exp: 2031-06-11→ Common Stock (35,562 underlying)
Other
Stock Option (right to buy)
2025-07-08−56,322→ 0 total
Exercise: $5.70Exp: 2033-06-01→ Common Stock (56,322 underlying)

Footnotes (4)

[F1]Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
[F2]In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
[F3]Disposition of options pursuant to Merger Agreement.
[F4]Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.

Documents

1 file